Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies

Background: BRAF (v-raf murine sarcoma viral oncogene homolog B1) and MEK (mitogen activated protein kinase) inhibitors, as well as immunotherapy against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) receptor and its ligand (PD-L1), have shown good resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Dika, Emi, Lambertini, Martina, Gouveia, Bruna, Mussi, Martina, Marcelli, Emanuela, Campione, Elena, Gurioli, Carlotta, Melotti, Barbara, Alessandrini, Aurora, Ribero, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003791/
https://www.ncbi.nlm.nih.gov/pubmed/33808846
http://dx.doi.org/10.3390/jcm10061283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003791/
https://www.ncbi.nlm.nih.gov/pubmed/33808846
http://dx.doi.org/10.3390/jcm10061283

Ejemplares similares